Skip to contentB
Boston Scientific Corp
B
BSXBoston Scientific Corp Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.29B$5.29Bderived+15.8% vs Q4 2024 Net Income$670.00M$670.00Mderived+19.0% vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Boston Scientific Corp · CIK 885725 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$3,678,000,000+18.8% Operating Incomederived$825,000,000+22.2% Operating Cash Flowderived$1,364,000,000−6.3% Free Cash Flowderived$1,013,000,000−14.1% Margins · derivedGross margin69.6%+1.8 pt vs Q4 2024
Operating margin15.6%+0.8 pt vs Q4 2024
Net margin12.7%+0.3 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 17, 2026 · 48 d after period end